Welcome to our dedicated page for MNTA news (Ticker: MNTA), a resource for investors and traders seeking the latest updates and insights on MNTA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MNTA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MNTA's position in the market.
Momenta Pharmaceuticals (NASDAQ: MNTA) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act regarding the all-cash tender offer by Vigor Sub, Inc., a subsidiary of Johnson & Johnson, to acquire Momenta for $52.50 per share. The tender offer commenced on September 2, 2020, and is expected to close in early October 2020, pending remaining conditions. The transaction was unanimously approved by both companies' boards, and Momenta's board recommends that shareholders tender their shares.
Momenta Pharmaceuticals (Nasdaq: MNTA) has announced a definitive agreement for Johnson & Johnson to acquire the company for $52.50 per share in cash, totaling $6.5 billion. This price reflects a significant 70% premium over Momenta’s last closing price on August 18, 2020. The acquisition aims to advance Momenta’s portfolio, particularly its FcRn inhibitor nipocalimab, expected to enhance treatment options for autoimmune diseases. The transaction is anticipated to close in the second half of 2020, pending regulatory approvals.
Momenta Pharmaceuticals (NASDAQ: MNTA) will announce its Q2 2020 financial results on August 10, 2020, prior to market opening. The company is focused on developing biologic therapeutics for rare immune-mediated diseases. A conference call will be held on the same day at 8:30 a.m. ET to discuss the results and company updates. Participants can register for the call online. Forward-looking statements highlight various risks associated with product development, including unpredictability in safety and efficacy of clinical trials.
Momenta Pharmaceuticals (NASDAQ: MNTA) announced that the FDA has granted rare pediatric disease designation and orphan drug status for its drug candidate, nipocalimab, aimed at preventing hemolytic disease of the fetus and newborn (HDFN). HDFN results from blood type incompatibility between mother and fetus, causing fetal anemia. Nipocalimab is designed to inhibit pathogenic antibody transfer from mother to fetus, offering a non-invasive treatment alternative. The UNITY Trial for HDFN is currently enrolling participants, with promising results expected.
Momenta Pharmaceuticals announced positive topline data from its Phase 2 Vivacity-MG study of nipocalimab (M281) for generalized myasthenia gravis (gMG). The trial met its primary endpoint, showing a significant relationship between IgG reduction and MG-ADL clinical benefits (p<0.0001). Nipocalimab exhibited rapid and durable response across all doses, and was well tolerated with no discontinuation due to adverse events. The trial, initiated in April 2019, involved 68 patients and is expected to complete in Q3 2020, with further data release slated for Q4 2020.
Momenta Pharmaceuticals (NASDAQ: MNTA) reported Q1 2020 financial results, highlighting a 262% increase in product revenue to $8.7 million, primarily from GLATOPA sales. R&D expenses rose 22% to $34.2 million, while general and administrative costs fell 40% to $14.6 million. The net loss reduced to $39.6 million, or $0.34 per share, compared to $44.8 million, or $0.46 per share in Q1 2019. With $487.9 million in cash, the company anticipates non-GAAP operating expenses below $220 million for 2020 due to COVID-19 impacts. Key data readouts are expected in Q3 2020.
